XTalks

JULY 20, 2021

The Bougie Bark cookies are preservative-free and do not contain any fillers. Therefore, it’s only natural for companies to cater to this growing consumer market. There is exponential growth in the pet treat market and it is predicted to reach $72.6 In 2020, the pet treats global market made an estimated $21.4

Marketing 105

Marketing Branding Filler Packaging 105

XTalks

JUNE 1, 2022

BONESUPPORT received market authorization from the FDA for Cerament G, the first and only bone graft with antibiotic elution that is approved for the US market. BONESUPPORT has recently received market authorization from the US Food and Drug Administration (FDA) for Cerament G, its bone graft with antibiotic elution.

Filler 98

Filler FDA Approval Production Marketing 98

XTalks

APRIL 4, 2024

Let’s explore MALK Organics’ history, its competitors and what sets it apart in a fiercely competitive market. Its recent internal Series B investment round , led by Benvolio Group and Rotor Capital, underlines the brand’s significant growth and market potential. billion by 2032.

Branding 104

Branding Filler Production Marketing 104

XTalks

MAY 14, 2024

SweetLeaf Xylitol, the latest innovation from Wisdom Natural Brands, marks a significant development in the natural sweeteners market. SweetLeaf Xylitol is distinct because it contains pure xylitol without any additional fillers or additives, making it a perfect one-to-one substitute for sugar in cooking, baking and beverages.

Filler 52

Filler Branding Production Containment 52

Pharmacy Checkers

NOVEMBER 12, 2020

A drug is considered “FDA-approved” when the FDA approves the drug application of a manufacturer to market that drug in the United States. A foreign version of an FDA-approved drug is a finished pharmaceutical that has the active ingredient contained in the FDA-approved version and is approved in another country.

FDA Approval 62

FDA Approval Drugs Filler Manufacturing 62

The Pharma Data

OCTOBER 22, 2021

Novartis blazoned moment that it has inked an original agreement to work its manufacturing capacity and capabilities to address the COVID-19 epidemic by expanding its support of the filler and finish of the Pfizer-BioNTech COVID-19 vaccine. The specifics will be bared when we conclude specific agreements.

Vaccination 52

Vaccination Vaccine Filler Manufacturing 52

The Pharma Data

NOVEMBER 4, 2020

Supported by a sales force covering Canada and executing a business to business to consumer marketing approach, Crescita sells its non-prescription skincare products domestically through spas, medispas, and medical clinics, as well as internationally, through distributors.

Licensing 40

Licensing Licensing Dermatology Production 40